Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib versus vinblastine in newly diagnosed BRAF wild-type non-NF1 pediatric and AYA low-grade glioma
2020-005786-14Phase 2Active
- Sponsor
- Strasbourg University Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioma, Glioneuronal Neoplasm and pleomorphic xanthoastrocytoma (PXA) comparing Trametinib arm with Vinblastine arm (2 arms). Primary endpoint: 3-year progression-free survival. Started Jul 2021; status: active.
02
Drugs
trametinibvinblastine
03
Conditions
gliomaGlioneuronal Neoplasmpleomorphic xanthoastrocytoma (PXA)
Beyond the preview
Go deeper on 2020-005786-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005786-14.